Dishman Carbogen Amcis Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

- Ongoing co-investment with a Japanese customer: The second co-investment is expected to be completed during the next calendar year, adding capacity to provide more quantities to the customer (Page 25). - External Commercial Borrowing (ECB): Approved by RBI to raise funds at promoter entity level, which will be infused in the Indian entity primarily to prepay high-cost debt and finance future CapEx and working capital requirements (Pages 10, 14, 15). - CapEx of CHF 4.9 million incurred in Q1 FY27 (Page 9). - Technology transfers: One tech transfer from Switzerland to India done; three more in advanced discussions to transfer commercial products to India aiming for higher margins (Page 21). - Cost control and new market access activities ongoing in specialty business units (Page 5). No specific new large-scale capital investment projects detailed beyond these ongoing plans.

- Order income is picking up, though market pressure continues (Page 5). - Several big pharma audits resulted in positive outcomes, leading to acquisition of new projects (Page 5). - Over 13 late phase projects, including PPQ campaigns, in portfolio with multiple Phase II projects successfully transformed into late phase programs (Page 5). - More RFPs (Requests for Proposals) are being received, indicating increased interest, but revenue translation may extend into next financial year (Page 21). - Co-investment with Japanese clients progressing, expected completion next calendar year to provide additional capacity (Page 25). - A recent commercial product approval indicates potential for increasing order volumes (Page 5). - Current delays in orders affected Q1 revenue; some orders postponed to later half of financial year (Page 8). Overall, the orderbook indicates growing opportunities with some timing lags in revenue recognition.